A carregar...

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML

Bcr-abl kinase inhibitors have provided proof of principal that targeted therapy holds great promise for the treatment of cancer. However, despite the success of these agents in treating chronic myelogenous leukemia (CML), the majority of patients continue to present with minimal residual disease co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nair, Rajesh R., Tolentino, Joel, Hazlehurst, Lori A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3285111/
https://ncbi.nlm.nih.gov/pubmed/20382130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2010.04.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!